Compositions and Methods for Treatment and Prevention of Pyrexia in Horses

Abstract

Methods for treating and preventing pyrexia and other diseases in equines such as horses involving administering an oral pharmaceutical formulation containing metamizole are disclosed.

1 - 24 .(canceled) 
     
     
         25 . A pharmaceutical composition comprising 200 mg/ml to 750 mg/ml metamizole, wherein the pharmaceutical composition is for oral administration to equines. 
     
     
         26 . The pharmaceutical composition of  claim 25 , wherein the pharmaceutical composition is a gel or paste. 
     
     
         27 . The pharmaceutical composition of  claim 25 , wherein the concentration of metamizole in said pharmaceutical composition is from 400 mg/ml to 600 mg/ml. 
     
     
         28 . The pharmaceutical composition of  claim 25 , wherein said pharmaceutical composition comprises at least one polymeric excipient. 
     
     
         29 . The pharmaceutical composition of  claim 28 , wherein at least one polymeric excipient is selected from albumin, acacia, alginic acid (or alginate salts, e.g. sodium alginate), bentonite, carbomers, carboxymethylcellulose, carrageenan, cellusoses, cellulose ethers, chitosan derivatives, dextran, divinyl ether-maleic anhydride (DIVEMA), dydroxyethylcellulose, ethylcellulose, gelatin, guar gum, hyaluronic acid (HA), hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, N-(2-Hydroxypropyl) methacrylamide (HPMA), magnesium aluminum silicate, methylcellulose, pectins, polyacrylamides, polyacrylic acid (PAA), polyethylene glycol (PEG) and PEG conjugates, polyethylene oxides, polyoxamers, polyoxazoline, polyphosphates, polyphosphazenes, polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), polyvinyl pyrrolidone-vinyl acetate (PVP-VA), starch or starch based derivatives, tragacanth, and xanthan gum. 
     
     
         30 . (canceled) 
     
     
         31 . (canceled) 
     
     
         32 . The pharmaceutical composition of  claim 25 , wherein said pharmaceutical composition comprises at least one preservative agent. 
     
     
         33 . The pharmaceutical composition of  claim 32 , wherein the preservative agent is selected from alcohol, benzyl alcohol, bronopol, chlorbutol, chlorocreson, a paraben, butyl paraben, methyl paraben, propyl paraben, phenol, phenylethanol, sodium benzoate, potassium sorbate, sorbic acid, glycerin, and propylene glycol. 
     
     
         34 . The pharmaceutical composition of  claim 25 , wherein said pharmaceutical composition comprises at least one paraben. 
     
     
         35 . (canceled) 
     
     
         36 . (canceled) 
     
     
         37 . (canceled) 
     
     
         38 . The pharmaceutical composition of  claim 25 , wherein said pharmaceutical composition comprises xanthan gum. 
     
     
         39 . The pharmaceutical composition of  claim 38 , wherein the xanthan gum is present at a concentration of 5 mg/ml to 20 mg/ml. 
     
     
         40 . The pharmaceutical composition of  claim 25 , wherein said pharmaceutical composition comprises propylene glycol. 
     
     
         41 . The pharmaceutical composition of  claim 40 , wherein the propylene glycol is present at a concentration of 50 mg/ml to 200 mg/ml. 
     
     
         42 . The pharmaceutical composition of  claim 25 , wherein the composition comprises 500 mg/mL metamizole sodium monohydrate, 10 mg/ml xanthan gum, and 100 mg/ml propylene glycol, in an aqueous solution. 
     
     
         43 . (canceled) 
     
     
         44 . (canceled) 
     
     
         45 . The pharmaceutical composition of  claim 25 , wherein the metamizole is metamizole sodium monohydrate. 
     
     
         46 . The pharmaceutical composition of  claim 25 , wherein the pharmaceutical composition has a viscosity of 200 cps to 20,000 cps at 25° C. 
     
     
         47 . (canceled) 
     
     
         48 . (canceled) 
     
     
         49 . (canceled) 
     
     
         50 . The pharmaceutical composition of  claim 25 , wherein the pharmaceutical composition comprises benzyl alcohol. 
     
     
         51 . The pharmaceutical composition of  claim 50 , wherein the benzyl alcohol is present at a concentration of 1-50 mg/ml. 
     
     
         52 . (canceled) 
     
     
         53 . The pharmaceutical composition of  claim 25 , wherein the composition comprises metamizole at a concentration of 400 mg/ml to 600 mg/ml, xanthan gum at a concentration of 5 mg/ml to 20 mg/ml, and propylene glycol at a concentration of 50 mg/ml to 200 mg/ml.